The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement Publication The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement This article explores the overlooked yet critical role of early strategic planning for payer reimbursement…Certara2025 年 2 月 25 日
Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA) Fact Sheet 定量药理学在药物开发中的决策支持:基于模型的荟萃分析(MBMA) Whether you’re optimizing trial design or seeking strategic insights, Certara’s MBMA delivers the clarity and…Certara2025 年 2 月 19 日
Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling Video Certara Phoenix 平台 — 全球最值得信赖的药代动力学/药效学(PK/PD)分析与建模平台 Today’s drug candidates are more complex than ever. But with development decisions on the line,…Certara2025 年 2 月 12 日
Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease Poster 利用模拟结果为探索全人源抗 IL-6 抗体 TOUR006 治疗甲状腺眼病的 IIb 期试验确定剂量 Certara2025 年 2 月 7 日
Machine Learning for Population PK Model Selection: Theory and Practice On-Demand Webinar 机器学习在群体药代动力学模型选择中的应用:理论与实践 Three of Certara's expert modelers provide a gentle introduction to machine learning in our field.…Certara2025 年 2 月 7 日
Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling On-Demand Webinar Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate…Certara2025 年 2 月 7 日
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies Publication 针对复发难治性(R/R)骨髓纤维化(MF)及其他髓系或实体瘤恶性肿瘤患者的 Navtemadlin 群体药代动力学与药效学分析 This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…Certara2025 年 2 月 6 日
Understanding Variability in CAR-T Cell Therapy Kinetics Publication 了解 CAR-T 细胞疗法动力学的变异性 Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…Certara2025 年 1 月 23 日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) On-Demand Webinar 利用基于模型的荟萃分析 (MBMA) 解决药物开发难题 In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…Certara2025 年 1 月 9 日
AI in Life Sciences Finds an Early Success and Will Continue in 2025 Press Coverage AI in Life Sciences Finds an Early Success and Will Continue in 2025 Fran Brown highlights how AI in life sciences drives more precise drug development and reduces…Certara2024 年 12 月 24 日